期刊文献+

影响辛伐他汀降脂疗效的临床因素 被引量:3

Investigation of the Effects on Lipid - lowing Therapy of Simvastatin
下载PDF
导出
摘要 目的:探讨影响辛伐他汀降脂疗效的临床因素。方法:共入选105例血清胆固醇水平未达标且服用辛伐他汀的患者,采用多因素回归分析的方法,观察了年龄、性别、剂量、体重、吸烟以及糖尿病等对辛伐他汀降脂疗效的影响。结果:血清总胆固醇和非高密度脂蛋白水平的降低与年龄呈负相关,与辛伐他汀的剂量呈正相关。结论:年龄和辛伐他汀的剂量是影响辛伐他汀的重要因素。 Objective: To study the effects on lipid - lowing therapy of simvastatin. Methods: 105 patients whose serum cholesterol concentrations didn' t reach the target level and who were taking simvastatin were enrolled. We investigated the effects of age, sex, weight, smoke, dose and diabetic mellitus on lipid - lowing therapy of simvastatin with multinomial logistic regression.Results: There are positive correlationship between the changes of serum cholesterol level and non - high density lipoprotein cholesterol concentration and age, and there are negative correlationship between simvastatin' s dose and the changes of serum cholesterol level and non -high density lipoprotein cholesterol concentration. Conclusion: Age and simvastatin's dose play important roles in the lipid - lowing therapy of simvastatin.
出处 《中国医药导刊》 2003年第5期347-348,共2页 Chinese Journal of Medicinal Guide
关键词 辛伐他汀 降脂疗效 影响因素 年龄 用药剂量 Simvastatin Age Dose
  • 相关文献

参考文献7

  • 1Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Sandinavian Simvastatin Survival Study(4S). lancet, 1994, 344:1383 ~ 1389.
  • 2Sacks FM, Pfeffer MA, Moyee LA, et al. The effect of pravastatin on coronary events after myocasdial infarction in patients with average cholesterol levels. N Engl J Med, 1996, 335:1001 ~ 1009.
  • 3Ojala JP, Helve E, FAmholm C, et al, Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatnmat in familial and non - familial hypereholesterolaemia. J Item Med,1991, 230:397-405.
  • 4Neil HAW, Meijer GW, Roe LS, Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol - enriched fat spread.Atherosclerosis, 2001, 156: 329-337.
  • 5Hayashi R, Kogure S, Serum cholesterol level in normal people: association of serum cholesterol level with age and relative body weight. Jpn J Med,1987, 26:153 ~ 157.
  • 6Richter V, Rassoul F, Senger H, et al. HDL/ LDL- cholesterol, arteriosclerosis and age. ZFA, 1980, 35:359 ~ 364.
  • 7Roberts WC. The Rule of 5 and the rule of 7 in lipid - lowing by statin drugs. Am J Cardiol, 1997, 80:106 ~ 107.

同被引文献30

  • 1王振杰,田秀芝,李贤,陈祚,赵连成,周北凡,武阳丰,中国高胆固醇血症控制状况调查协作组.药物治疗的高胆固醇血症患者膳食治疗状况与血脂控制达标率——高胆固醇血症临床控制状况多中心协作研究[J].中华心血管病杂志,2005,33(4):372-375. 被引量:17
  • 2Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量:117
  • 3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5221
  • 4Gibson DM,Bron NJ,Richen A,et al.Effect of age and gender on pharmacokinetics of atorvastatin in humans[J].J Clin Pharmacol,1996 ;36:242-246.
  • 5Nakagami T,DECODA Study Group.Hyperlycaemia and motality from all causes and from cardiovascular disease in five populations of Asian origin[J].Diabetologia,2004;47:385-394.
  • 6Lawes CM,Parag V,Bennett DA,et al.Blood glucose and risk of cardiovascular disease in Asian Pacific origin[J].Diabetes Care,2004;27:2836-2842.
  • 7Nielson C,Lange T,Hadjokas N.Blood glucose and coronary artery disease in nondiabetic patients[J].Diabetes Care,2006;29:998-1001.
  • 8Lyons TJ.Lipoprotein qlycation and its metabolic consequences[J].Diabetes,1992 ;41:67-73.
  • 9Sasaki J,Iwashita M,Kono S.Statins:beneficial or adverse for glucose metabolism[J].J Atheroscler Thromb,2006,13(3):123-129.
  • 10Alegret M,Silvestre JS.Pleiotropic effects of statins and related pharmacological experimental approaches[J].Timely Top Med Cardiovasc Dis,2007,11:E10.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部